Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:AOXGNASDAQ:QLGNOTCMKTS:RSPIOTCMKTS:SEGI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAOXGAoxing Pharmaceutical$0.01$0.01$0.00▼$0.02$2.90M7.2265,246 shsN/AQLGNQualigen Therapeutics$3.87-1.8%$3.40$2.85▼$29.44$2.85M-0.07113,706 shs38,009 shsRSPIRespireRx Pharmaceuticals$0.00$0.00$0.00▼$0.01$1.71M0.43508,210 shs30 shsSEGISycamore Entertainment Group$0.00+40.0%$0.00$0.00▼$0.00$3.55M60.462.29 million shs4.06 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAOXGAoxing Pharmaceutical0.00%+15.15%-5.00%0.00%+5.56%QLGNQualigen Therapeutics0.00%+7.80%+20.56%+4.34%-74.77%RSPIRespireRx Pharmaceuticals0.00%+157.14%-5.26%-10.00%+100.00%SEGISycamore Entertainment Group0.00%+40.00%-12.50%-12.50%+16.67%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAOXGAoxing PharmaceuticalN/AN/AN/AN/AN/AN/AN/AN/AQLGNQualigen TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ARSPIRespireRx PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ASEGISycamore Entertainment GroupN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAOXGAoxing Pharmaceutical 0.00N/AN/AN/AQLGNQualigen Therapeutics 0.00N/AN/AN/ARSPIRespireRx Pharmaceuticals 0.00N/AN/AN/ASEGISycamore Entertainment Group 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAOXGAoxing PharmaceuticalN/AN/AN/AN/AN/AN/AQLGNQualigen Therapeutics$4.98M0.57N/AN/A($20.31) per share-0.19RSPIRespireRx PharmaceuticalsN/AN/AN/AN/AN/AN/ASEGISycamore Entertainment GroupN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAOXGAoxing PharmaceuticalN/AN/A0.00∞N/AN/AN/AN/AN/AQLGNQualigen Therapeutics-$13.42MN/A0.00∞N/AN/AN/A-424.18%5/19/2025 (Estimated)RSPIRespireRx Pharmaceuticals-$2.10MN/A0.00∞N/AN/AN/AN/AN/ASEGISycamore Entertainment GroupN/AN/A0.00∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAOXGAoxing PharmaceuticalN/AN/AN/AN/AN/AQLGNQualigen TherapeuticsN/AN/AN/AN/AN/ARSPIRespireRx PharmaceuticalsN/AN/AN/AN/AN/ASEGISycamore Entertainment GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAOXGAoxing PharmaceuticalN/AN/AN/AQLGNQualigen TherapeuticsN/A0.520.52RSPIRespireRx PharmaceuticalsN/AN/AN/ASEGISycamore Entertainment GroupN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAOXGAoxing PharmaceuticalN/AQLGNQualigen Therapeutics3.18%RSPIRespireRx PharmaceuticalsN/ASEGISycamore Entertainment GroupN/AInsider OwnershipCompanyInsider OwnershipAOXGAoxing Pharmaceutical17.80%QLGNQualigen Therapeutics1.80%RSPIRespireRx Pharmaceuticals50.03%SEGISycamore Entertainment Group75.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAOXGAoxing Pharmaceutical350381.21 million313.35 millionNot OptionableQLGNQualigen Therapeutics50736,000723,000Not OptionableRSPIRespireRx Pharmaceuticals2949.46 million474.45 millionNot OptionableSEGISycamore Entertainment GroupN/A5.07 billionN/ANot OptionableRSPI, QLGN, SEGI, and AOXG HeadlinesRecent News About These CompaniesNew Sycamore faces getting to know each other as practices beginSeptember 25, 2024 | sports.yahoo.comSycamore Entmt Grp (SEGI)August 30, 2024 | investing.comChristian McGuigan and Timothy Reckart Launch Sycamore Studios (EXCLUSIVE)August 28, 2024 | variety.comSycamore High School students turn 'juke box heroes' as choir prepares to share stage with ForeignerAugust 21, 2024 | wcpo.comSycamore lineman has team improvement, family legacy in mindAugust 17, 2024 | sports.yahoo.comSETY Star Entertainment Group Inc.August 1, 2024 | seekingalpha.comSycamore Entmt Grp (SEGI) Earnings Dates & ReportsMay 28, 2024 | investing.comSycamore Entertainment Group, Inc. (SEGI)May 18, 2024 | finance.yahoo.comDesigner House the latest chapter of Sycamore Lane Farm’s storyApril 25, 2024 | buckscountyherald.comX1 Entertainment Group Inc XONEApril 17, 2024 | morningstar.comSycamore Entertainment Group Inc.March 24, 2024 | wsj.comSkyCity Entertainment Group Limited (ASX: SKC) - Share Price and ResearchMarch 22, 2024 | intelligentinvestor.com.auSycamore Manor resident celebrates 92nd birthdayMarch 17, 2024 | msn.com'Just plain sloppy': After complaints mount at Sycamore Place apartments, owners vow improvementsFebruary 14, 2024 | msn.comSycamore 13-year-old faces domestic battery chargesJanuary 3, 2024 | wifr.comLawyer from Wrexham University explains why police haven't solved Sycamore Gap tree case yetOctober 28, 2023 | walesonline.co.ukWarsaw community comes together to save 275-year-old Sycamore treeOctober 28, 2023 | wndu.comAPD investigating homicide on West SycamoreOctober 18, 2023 | kalb.comSuspect wannted in connection with West Sycamore Street homicideOctober 18, 2023 | msn.com‘It’s been a constant struggle’: Sycamore Valley residents fed up after living without water for several daysOctober 11, 2023 | click2houston.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRSPI, QLGN, SEGI, and AOXG Company DescriptionsAoxing Pharmaceutical OTCMKTS:AOXG$0.0076 0.00 (0.00%) As of 05/16/2025Aoxing Pharmaceutical Company, Inc. a specialty pharmaceutical company, engages in research and development, manufacture, and distribution of narcotic, pain-management, and addiction treatment pharmaceutical products primarily in the People's Republic of China. The company's principal products include Zhongtong'an, a capsule of herbal extraction for the indication of oral and dental pain; and Yiqi Qiangshen Granule, an OTC herbal extraction for tonifying qi and empowering body, and promoting blood circulation to remove meridian obstruction, as well as Tilidine hydrochloride, an orally-absorbed synthetic narcotic analgesic tablet used in 50mg or 100mg dosage for relief of acute, moderate to severe pain, and chronic cancer-related pain. Its products under development comprise Oxycodone and Acetaminophen tablets and capsules, which has completed clinical trials for the treatment of acute and chronic pain; Buprenorphine/Naloxone, a sublingual combo tablet that has completed Phase II clinical trials for the treatment of opioid dependence; and Tilidine/Naloxone, a compound capsule which is in Phase II clinical trial to treat acute and chronic pain. The company was formerly known as China Aoxing Pharmaceutical Company, Inc. and changed its name to Aoxing Pharmaceutical Company, Inc. in March 2010. Aoxing Pharmaceutical Company, Inc. is headquartered in Shijiazhuang, China.Qualigen Therapeutics NASDAQ:QLGN$3.87 -0.07 (-1.78%) Closing price 05/16/2025 04:00 PM EasternExtended Trading$3.94 +0.07 (+1.81%) As of 05/16/2025 05:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Qualigen Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.RespireRx Pharmaceuticals OTCMKTS:RSPI$0.0018 0.00 (0.00%) As of 05/16/2025RespireRx Pharmaceuticals Inc. engages in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. It has two drug platforms comprising ResolutionRx, a pharmaceutical cannabinoids platform, which includes dronabinol that acts upon the CB1 and CB2 endocannabinoid receptors for use in chemotherapy-induced nausea and vomiting, as well as for anorexia in patients with AIDS and obstructive sleep apnea; and EndeavourRx, a neuromodulators platform that comprises AMPAkines program, including proprietary compounds that are positive allosteric modulators (PAMs) of glutamate receptors to promote neuronal function, and GABAkines program, including proprietary compounds that are PAMs of GABAA receptors. The company's lead ampakine, CX1739, which has completed Phase II clinical studies for opioid-induced respiratory depression, as well as for central sleep apnea. It is also developing CX717, CX1739, and CX1942 that have clinical application in the treatment of CNS-driven neurobehavioral and cognitive disorders, spinal cord injury, neurological diseases, and various orphan indications. It has a research collaboration with University College London to the use of AMPAkines for the treatment of GRIA disorders. The company was formerly known as Cortex Pharmaceuticals, Inc. and changed its name to RespireRx Pharmaceuticals Inc. in December 2015. RespireRx Pharmaceuticals Inc. was incorporated in 1987 and is headquartered in Glen Rock, New Jersey.Sycamore Entertainment Group OTCMKTS:SEGI$0.0007 +0.00 (+40.00%) As of 05/16/2025 02:48 PM EasternSycamore Entertainment Group, Inc., a diversified entertainment company, which specializes in the acquisition, marketing, and worldwide distribution of feature-length motion pictures. The company is based in Seattle, Washington. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/12 - 05/16 Retail Investors Are Betting Big on Rocket Lab—Should You Too? Meta's 5 Key Pillars for AI Growth—Zuckerberg's Bold Vision Taiwan Semiconductor Stock Is The Gift That Keeps on Giving GE Aerospace: Qatar Deal Fuels Multi-Billion Dollar Growth Engine Alibaba's Earnings Just Changed Everything for the Stock Plug Power: Is Q1 Noise An Opportunity for Accumulation? Cisco Stock Eyes New Highs in 2025 on AI, Earnings, Upgrades Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
